These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 37452493)

  • 1. A dysfunctional miR-1-TRPS1-MYOG axis drives ERMS by suppressing terminal myogenic differentiation.
    Hüttner SS; Henze H; Elster D; Koch P; Anderer U; von Eyss B; von Maltzahn J
    Mol Ther; 2023 Sep; 31(9):2612-2632. PubMed ID: 37452493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
    Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
    Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4.
    Nanni P; Nicoletti G; Palladini A; Astolfi A; Rinella P; Croci S; Landuzzi L; Monduzzi G; Stivani V; Antognoli A; Murgo A; Ianzano M; De Giovanni C; Lollini PL
    Mol Cancer Ther; 2009 Apr; 8(4):754-61. PubMed ID: 19372547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between SNAI2 and MYOD enhances oncogenesis and suppresses differentiation in Fusion Negative Rhabdomyosarcoma.
    Pomella S; Sreenivas P; Gryder BE; Wang L; Milewski D; Cassandri M; Baxi K; Hensch NR; Carcarino E; Song Y; Chou HC; Yohe ME; Stanton BZ; Amadio B; Caruana I; De Stefanis C; De Vito R; Locatelli F; Chen Y; Chen EY; Houghton P; Khan J; Rota R; Ignatius MS
    Nat Commun; 2021 Jan; 12(1):192. PubMed ID: 33420019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells.
    Megiorni F; Gravina GL; Camero S; Ceccarelli S; Del Fattore A; Desiderio V; Papaccio F; McDowell HP; Shukla R; Pizzuti A; Beirinckx F; Pujuguet P; Saniere L; der Aar EV; Maggio R; De Felice F; Marchese C; Dominici C; Tombolini V; Festuccia C; Marampon F
    J Hematol Oncol; 2017 Oct; 10(1):161. PubMed ID: 28985758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation.
    Megiorni F; Camero S; Ceccarelli S; McDowell HP; Mannarino O; Marampon F; Pizer B; Shukla R; Pizzuti A; Marchese C; Clerico A; Dominici C
    Oncotarget; 2016 Nov; 7(48):79342-79356. PubMed ID: 27764816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells.
    De Salvo M; Raimondi L; Vella S; Adesso L; Ciarapica R; Verginelli F; Pannuti A; Citti A; Boldrini R; Milano GM; Cacchione A; Ferrari A; Collini P; Rosolen A; Bisogno G; Alaggio R; Inserra A; Locatelli M; Stifani S; Screpanti I; Miele L; Locatelli F; Rota R
    PLoS One; 2014; 9(5):e96238. PubMed ID: 24797362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired Wnt signaling in embryonal rhabdomyosarcoma cells from p53/c-fos double mutant mice.
    Singh S; Vinson C; Gurley CM; Nolen GT; Beggs ML; Nagarajan R; Wagner EF; Parham DM; Peterson CA
    Am J Pathol; 2010 Oct; 177(4):2055-66. PubMed ID: 20829439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma.
    Coda DM; Lingua MF; Morena D; Foglizzo V; Bersani F; Ala U; Ponzetto C; Taulli R
    Cell Cycle; 2015; 14(9):1389-402. PubMed ID: 25644430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SIX1 reprograms myogenic transcription factors to maintain the rhabdomyosarcoma undifferentiated state.
    Hsu JY; Danis EP; Nance S; O'Brien JH; Gustafson AL; Wessells VM; Goodspeed AE; Talbot JC; Amacher SL; Jedlicka P; Black JC; Costello JC; Durbin AD; Artinger KB; Ford HL
    Cell Rep; 2022 Feb; 38(5):110323. PubMed ID: 35108532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CASZ1 induces skeletal muscle and rhabdomyosarcoma differentiation through a feed-forward loop with MYOD and MYOG.
    Liu Z; Zhang X; Lei H; Lam N; Carter S; Yockey O; Xu M; Mendoza A; Hernandez ER; Wei JS; Khan J; Yohe ME; Shern JF; Thiele CJ
    Nat Commun; 2020 Feb; 11(1):911. PubMed ID: 32060262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.
    Yohe ME; Gryder BE; Shern JF; Song YK; Chou HC; Sindiri S; Mendoza A; Patidar R; Zhang X; Guha R; Butcher D; Isanogle KA; Robinson CM; Luo X; Chen JQ; Walton A; Awasthi P; Edmondson EF; Difilippantonio S; Wei JS; Zhao K; Ferrer M; Thomas CJ; Khan J
    Sci Transl Med; 2018 Jul; 10(448):. PubMed ID: 29973406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-183-5p induced by saturated fatty acids regulates the myogenic differentiation by directly targeting FHL1 in C2C12 myoblasts.
    Nguyen MT; Min KH; Lee W
    BMB Rep; 2020 Nov; 53(11):605-610. PubMed ID: 33148375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor-I has different effects on myogenin induction and cell cycle progression in human alveolar and embryonal rhabdomyosarcoma cells.
    Tsuchiya K; Hosoi H; Misawa-Furihata A; Houghton PJ; Sugimoto T
    Int J Oncol; 2007 Jul; 31(1):41-7. PubMed ID: 17549403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the Notch-Hey1 axis blocks embryonal rhabdomyosarcoma tumorigenesis.
    Belyea BC; Naini S; Bentley RC; Linardic CM
    Clin Cancer Res; 2011 Dec; 17(23):7324-36. PubMed ID: 21948088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alveolar rhabdomyosarcoma-associated proteins PAX3/FOXO1A and PAX7/FOXO1A suppress the transcriptional activity of MyoD-target genes in muscle stem cells.
    Calhabeu F; Hayashi S; Morgan JE; Relaix F; Zammit PS
    Oncogene; 2013 Jan; 32(5):651-62. PubMed ID: 22710712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS.
    Ciarapica R; Carcarino E; Adesso L; De Salvo M; Bracaglia G; Leoncini PP; Dall'agnese A; Verginelli F; Milano GM; Boldrini R; Inserra A; Stifani S; Screpanti I; Marquez VE; Valente S; Mai A; Puri PL; Locatelli F; Palacios D; Rota R
    BMC Cancer; 2014 Feb; 14():139. PubMed ID: 24575771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RAGE signaling deficiency in rhabdomyosarcoma cells causes upregulation of PAX7 and uncontrolled proliferation.
    Riuzzi F; Sorci G; Sagheddu R; Sidoni A; Alaggio R; Ninfo V; Donato R
    J Cell Sci; 2014 Apr; 127(Pt 8):1699-711. PubMed ID: 24554430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A chimeric RNA characteristic of rhabdomyosarcoma in normal myogenesis process.
    Yuan H; Qin F; Movassagh M; Park H; Golden W; Xie Z; Zhang P; Sklar J; Li H
    Cancer Discov; 2013 Dec; 3(12):1394-403. PubMed ID: 24089019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma.
    Zibat A; Missiaglia E; Rosenberger A; Pritchard-Jones K; Shipley J; Hahn H; Fulda S
    Oncogene; 2010 Dec; 29(48):6323-30. PubMed ID: 20818440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.